BIOGEN INC. Finite-Lived Intangible Asset, Expected Amortization, Year One
BIOGEN INC. (BIIB) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $485.00 million as of 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2026-04-29
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $485.00M.
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $485.00M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $485.00M.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $565.00M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2026-03-31 | $485.00M 10-Q · filed 2026-04-29 |
| 2025-12-31 | $485.00M 10-K · filed 2026-02-06 |
| 2025-09-30 | $485.00M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $565.00M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $560.00M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $525.00M 10-K · filed 2025-02-12 |
| 2024-09-30 | $510.00M 10-Q · filed 2024-10-30 |
| 2024-06-30 | $565.00M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $565.00M 10-Q · filed 2024-04-24 |
| 2023-12-31 | $345.00M 10-K · filed 2024-02-14 |
| 2023-09-30 | $325.00M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $200.00M 10-Q · filed 2023-07-25 |
| 2023-03-31 | $195.00M 10-Q · filed 2023-04-25 |
| 2022-12-31 | $215.00M 10-K · filed 2023-02-15 |
| 2022-09-30 | $215.00M 10-Q · filed 2022-10-25 |
| 2022-06-30 | $210.00M 10-Q · filed 2022-07-20 |
| 2022-03-31 | $210.00M 10-Q · filed 2022-05-03 |
| 2021-12-31 | $255.00M 10-K · filed 2022-02-03 |
| 2021-09-30 | $255.00M 10-Q · filed 2021-10-20 |
| 2021-06-30 | $215.00M 10-Q · filed 2021-07-22 |
| 2021-03-31 | $215.00M 10-Q · filed 2021-04-22 |
| 2020-12-31 | $205.00M 10-K · filed 2021-02-03 |
| 2020-09-30 | $205.00M 10-Q · filed 2020-10-21 |
| 2020-06-30 | $220.00M 10-Q · filed 2020-07-22 |
| 2020-03-31 | $220.00M 10-Q · filed 2020-04-23 |
| 2019-12-31 | $260.00M 10-K · filed 2020-02-06 |
| 2019-09-30 | $255.00M 10-Q · filed 2019-10-22 |
| 2019-06-30 | $255.00M 10-Q · filed 2019-07-24 |
| 2019-03-31 | $290.00M 10-Q · filed 2019-04-24 |
| 2018-12-31 | $270.00M 10-K · filed 2019-02-06 |
| 2018-09-30 | $367.00M 10-Q · filed 2018-10-23 |
| 2018-06-30 | $402.60M 10-Q · filed 2018-07-24 |
| 2018-03-31 | $402.60M 10-Q · filed 2018-04-24 |
| 2017-12-31 | $423.50M 10-K · filed 2018-02-01 |
| 2017-09-30 | $421.30M 10-Q · filed 2017-10-24 |
| 2017-06-30 | $425.80M 10-Q · filed 2017-07-25 |
| 2017-03-31 | $425.50M 10-Q · filed 2017-04-25 |
| 2016-12-31 | $334.80M 10-K · filed 2017-02-02 |
| 2016-09-30 | $347.80M 10-Q · filed 2016-10-26 |
| 2016-06-30 | $325.10M 10-Q · filed 2016-07-21 |
| 2016-03-31 | $321.00M 10-Q · filed 2016-04-21 |
| 2015-12-31 | $346.40M 10-K · filed 2016-02-03 |
| 2015-09-30 | $348.80M 10-Q · filed 2015-10-21 |
| 2015-06-30 | $312.50M 10-Q · filed 2015-07-24 |
| 2015-03-31 | $313.30M 10-Q · filed 2015-04-24 |
| 2014-12-31 | $344.30M 10-K · filed 2015-02-04 |
| 2014-09-30 | $345.20M 10-Q · filed 2014-10-22 |
| 2014-06-30 | $333.40M 10-Q · filed 2014-07-23 |
| 2014-03-31 | $334.70M 10-Q · filed 2014-04-23 |
| 2013-12-31 | $426.30M 10-K · filed 2014-02-06 |
| 2013-09-30 | $418.90M 10-Q · filed 2013-10-28 |
| 2013-06-30 | $165.60M 10-Q · filed 2013-07-25 |
| 2013-03-31 | $277.00M 10-Q · filed 2013-04-25 |
| 2012-12-31 | $207.40M 10-K · filed 2013-02-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |